The effects of crocin on the symptoms of depression in subjects with metabolic syndrome

Jam, Irandokht Nikbakht; Sahebkar, Amirhosein; Eslami, Saeid; Mokhber, Naghmeh; Nosrati, Mina; Khademi, Mohammad; Foroutan-Tanha, Mojtaba; Ghayour‐Mobarhan, Majid; Hadizadeh, Farzin; Ferns, Gordon A.; Abbasi, Masoumeh

doi:10.17219/acem/62891

Cited by 44 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with the findings of animal studies, the results of our study showed that hesperidin could reduce the severity of depression in patients with mild depression. So, to the best of our knowledge, no clinical trial has been conducted in this area, but a limited number of clinical trials have investigated the effects of other phytochemicals such as curcumin, resveratrol, and crocin on depression (Jam et al, 2017; Kanchanatawan et al, 2018; Lopresti, 2017; Malaguarnera et al, 2018). A review of animal and human studies by Lopresti also concluded that curcumin might be an effective antidepressant for patients with major depressive disorder (Lopresti, 2017).…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, taking 19.8 mg of resveratrol in oral pills for 90 days in subjects aged 39 and 60 with moderate depression and 15 mg crocin in oral tablets twice daily for 8 weeks in subjects with a mean age of 48 years and mild depression reduced the severity of symptoms. Both studies also included placebo groups (Jam et al, 2017; Malaguarnera et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hesperidin reduces depressive symptoms in post‐coronary artery bypass graft patients with mild depression

Khorasanian,

Jazayeri,

Omidi

et al. 2023

Food Science & Nutrition

View full text Add to dashboard Cite

Previous studies have shown that hesperidin may have beneficial effects on depression; however, to the best of our knowledge, no clinical trial has yet been conducted in this area. The aim of the present study was, therefore, to determine the effects of hesperidin on depression, serum brain‐derived neurotrophic factor (BDNF), and serum cortisol levels in post‐coronary artery bypass graft (CABG) patients. Toward this goal, 73 post‐CABG patients with depression symptoms were enrolled. The participants were randomly divided into two groups to receive either 200 mg/day hesperidin (n = 38) or placebo (n = 35) for 12 weeks. Depressive symptoms, serum BDNF, and cortisol levels were then assessed at the baseline and after intervention. Beck Depression Inventory‐II (BDI‐II) was also used to determine the severity of depression. Sixty‐six patients completed the trial. Hesperidin decreased depression severity after 12 weeks, as compared to placebo (p = .004), but serum BDNF and cortisol were not statistically significantly different in the two groups after the intervention. Subgroup analyses also showed that, while in the patients with mild depression, the score of BDI‐II was significantly different in the hesperidin and placebo groups after intervention; there was no difference in the severity of depression between the two groups in patients with moderate‐to‐severe depression. To conclude, a dose of 200 mg/day hesperidin may reduce depressive symptoms after 12 weeks in post‐CABG patients with mild depression.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Hesperidin reduces depressive symptoms in post‐coronary artery bypass graft patients with mild depression

Khorasanian,

Jazayeri,

Omidi

et al. 2023

Food Science & Nutrition

View full text Add to dashboard Cite

show abstract

“…For patients with mild to moderate depression, saffron significantly reduced the severity of symptoms, compared with placebo. [21][22][23][24][25]27,28,[39][40][41] Of note, 1 trial 41 administered an extract of C. sativus petals and observed significant improvement, compared with controls. Because crocin is largely absent from petal extracts, this suggests that portions of the C. sativus plant other than stigmas may be a source of bioactive and possibly less expensive compounds.…”

Section: Potential Health Benefitsmentioning

confidence: 99%

Saffron

2023

Nutr Today

View full text Add to dashboard Cite

“…A previous review study has reported the efficacy of crocin in the improvement of a wide-range of mental disorders like major depressive disorder, depression, postpartum and post-menopausal depression, and obsessive compulsive disorder (OCD) (Omidkhoda and Hosseinzadeh, 2022). Crocin reduces the symptoms of depression in subjects with metabolic syndrome (Jam et al ., 2017). Other study has shown that crocin potently prevents anxiety and depressive-like behaviors induced by unpredictable chronic mild stress in rats (Abbaszade-Cheragheali et al ., 2022).…”

Section: Introductionmentioning

confidence: 99%

Crocin (bioactive compound of Crocus sativus L.) potently restores REM sleep deprivation-induced manic- and obsessive-compulsive-like behaviors in female rats

Houshyar,

Karimi,

Ghofrani-Jahromi

et al. 2024

Behavioural Pharmacology

View full text Add to dashboard Cite

Rapid-eye movement (REM) sleep deprivation (SD) can induce manic-like behaviors including hyperlocomotion. On the other hand, crocin (one of the main compounds of Crocus sativus L. or Saffron) may be beneficial in the improvement of mental and cognitive dysfunctions. Also, crocin can restore the deleterious effects of SD on mental and cognitive processes. In this study, we investigated the effect of REM SD on female rats’ behaviors including depression- and anxiety-like behaviors, locomotion, pain perception, and obsessive-compulsive-like behavior, and also, the potential effect of crocin on REM SD effects. We used female rats because evidence on the role of REM SD in modulating psychological and behavioral functions of female (but not male) rats is limited. REM SD was induced for 14 days (6h/day), and crocin (25, 50, and 75 mg/kg) was injected intraperitoneally. Open field test, forced swim test, hot plate test, and marble burying test were used to assess rats’ behaviors. The results showed REM SD-induced manic-like behavior (hyperlocomotion). Also, REM SD rats showed decreased anxiety- and depression-like behavior, pain subthreshold (the duration it takes for the rat to feel pain), and showed obsessive compulsive-like behavior. However, crocin at all doses partially or fully reversed REM SD-induced behavioral changes. In conclusion, our results suggested the possible comorbidity of OCD and REM SD-induced manic-like behavior in female rats or the potential role of REM SD in the etiology of OCD, although more studies are needed. In contrast, crocin can be a possible therapeutic choice for decreasing manic-like behaviors.

show abstract

The effects of crocin on the symptoms of depression in subjects with metabolic syndrome

Abstract: This study demonstrates that at a dose of 30 mg per day for 8 weeks, crocin reduced the symptoms of depression in subjects with MetS compared to the control group, and this effect was independent of its effect on the serum PAB.

Cited by 44 publications

References 23 publications

Hesperidin reduces depressive symptoms in post‐coronary artery bypass graft patients with mild depression

Hesperidin reduces depressive symptoms in post‐coronary artery bypass graft patients with mild depression

Saffron

Crocin (bioactive compound of Crocus sativus L.) potently restores REM sleep deprivation-induced manic- and obsessive-compulsive-like behaviors in female rats

Contact Info

Product

Resources

About